| Price | $205.15 |
| Year Range | $164.42 – $216.63 |
| Market Cap | $30.7B |
| PE Ratio | 36.87 |
| Industry | Biotechnology |
What Is Biogen’s AI Stock Analysis?
Biogen’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Biogen’s momentum in near-real time.
Biogen (BIIB) has an AltIndex AI Score of 34/100, currently a Sell signal. The AI Score distills Biogen's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Biogen’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Biogen — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving BIIB’s AI Score?
Fundamentals
Revenue for the last quarter was $2.48B. This is an increase of 8.71% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 1.93%, suggesting positive year-over-year growth. Net income for the last quarter was $320M. This is an increase of -759.97% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 32.85%, suggesting positive year-over-year growth. Ebitda for the last quarter was $554M. This is an increase of 85.34% compared to the quarter before it, which is a positive sign of growth. However, compared to the same quarter last year, there is a decrease of 36.01%, which may be a cause for concern. The current P/E ratio is 36.87. This may be considered high, potentially indicating overvaluation and a bearish outlook.
See Biogen’s earnings and insider transactions.
Technicals
Today's stock price is $205.15. This is an increase of 3.01% compared to a month ago, indicating a positive short-term trend. Compared to a year ago, there is an increase of 59.12%, suggesting a positive long-term trend. The trend is bullish. The current SMA10 is $206.22, which is higher than the previous SMA10 of $206.00. This indicates a potential upward trend in price movement. The RSI is 69.9, indicating a neutral condition.
See the full technical analysis and price prediction.
Alternative data
Biogen has an estimated 233 open positions and this number has been stable over the last couple of months indicating a company in a stable position. The business outlook among employees at Biogen is neutral. Biogen has an estimate of 110,000 visitors to their webpage. The number of visitors is down by -20% in the last couple of months, a worrisome trend as this can indicate a loss in customers.
Explore Biogen’s job postings, web traffic and app downloads.
Sentiment & social
The sentiment for the stock on various stock forums is very high, a positive sign. Biogen has 45,000 followers on their Twitter page. The number of followers is down by -0% in the last couple of months, indicating a loss in interest in the company.
Track Biogen’s market sentiment.
Frequently Asked Questions: Biogen AI Stock Analysis
Biogen's AltIndex AI Score is 34/100, currently a Sell signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Biogen a Sell (34/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Biogen — company overview, fundamentals, technicals and alternative data, with a recommendation. See the BIIB AI Score or sign up to read the full thesis.
